AVIR - Earnings call 4 2023 | Atea Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Fourth Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions] I would now like to turn the call over to Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Ms. Barnes, please proceed.

Jonae Barnes

Good afternoon, everyone, and welcome to Atea Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call. a discuss. which issued we the we to plan today, press outlines release, topics Earlier

access press Chief and going Andrea can . With Executive we'll Medical section You Officer Dr. the our They me be be slides Janet as Financial today's our of Officer Officer, Dr. are reviewing Corcoran; that today Vavricka. the and from Officer; today our Legal, at Hammond; call. of Founder; by Development Executive Officer, website Chief to Chief President will Atea Investors [indiscernible], available release the ir.ateapharma.com. as Dr. Chief Q&A well Sommadossi; Vice John for Commercial and portion Chief all the Jean-Pierre of

on remind statements risks like in Slide X, Securities which Before we recent today's begin uncertainties. encourage risks outlined we I Exchange in filings you Commission, with contain release forward-looking today's press to outlined to discussion that will read. involve uncertainties are you These and and the call, and as and company's that would the the and

from Our over is results to materially the With what now differ may call. Jean-Pierre. discussed on call that, I'll actual today's turn

Jean-Pierre Sommadossi

begin thank Jonae. everyone, you, afternoon, I X. for Slide and Good us. joining will Thank on you

COVID-XX substantial our for broadening III Looking program patients. III eligibility This the the by Phase global achieved strong operational include made across our I'm footprint expansion SUNRISE study. ability back global of searches meaningfully high-risk the to execution advance at progress criteria from proud the of our leverage we the XXXX was and possible The our XXXX. throughout of highlights the antiviral to programs.

Sunrise. encouraging XXXX, in far for to observe trends we So enrollment continue

track the medical evaluation were granted for designation for Casebia Reflecting the the need, COVID-XX. we continuing by unmet of Beni FDA fast

remain including efficacy the by related key bemnifosbuvir with against now potential to and [indiscernible] clinical binifatovia data of no direct The the active We variants the therapies. oral vitro, We in the favorable believe to robust that for address is has fully all supported bemnifosbuvir COVID-XX surveillance including drug interaction. tested to omicron. demonstrate have continued profile limitations safety that

the highlights achieving short X-week leading the cohort, the demonstrated led Ruzasvir trial We SVR combination HCV a of will the of in of the treatment treatment regulatory of include potency approvals today. and major against bemnifosbuvir The exciting which the HCV, II combination comparing Phase of for For XXXX enrollment vitro global synergy has rapid and HCV. bemnifosbuvir that results for resistance to of and mutations. review of the profile Ruzasvir we

several offering of and program We by a this program. has fixed-dose potential preclinical preparation with for are current And now combination evaluating short We improve the treatment, inhibitor the been combination weeks published we commercialization. for subsequent upon presented in can standard data support III care protease clinical tablets interactions. significantly bemnifosbuvir differentiated and in tolerated free and limited drug-drug of believe and has X which Ruzasvir well Phase

treatment and significant Slide huge is on is viral need of drugs a development there the and can cure we and antiviral focused to difference. discovery Moving a of vision for serious medical Atea where where diseases make the X. unmet

booster winter believe search the thriving stay. COVID And here and we despite like new that are dominant know, is the [indiscernible] treatments. you As us to recent variants remind vaccine that latest

and well other amino oral highlighting than arsenal and Sars-CoV-X broader substitutions RNA acid antiviral mutations therapeutics. easy for any desperate safe, endemic the tolerated faster more of with prescribe to accumulating The is virus diversified vans, need

supportive significant we to clinical X,XXX interim our achieved Our care team patients, enrollment another have announce surpass in today efficiently and continues and triggering the analysis trial, I'm III pleased to milestone Phase of second monotherapy global execute that cohort. our very

the for review allowing futility. an DSMB data the is safety important independent by milestone, and for This

Sunrise-X, the XXXX. therapies, mutations analysis half XXXX interim interactions. analysis many of quarter reliability in anticipate of the the March, potential the and including the current of key second several Bemnifosbuvir in and has address interim first second including during safety, drug-drug second of the For to we top events, upcoming to line results COV-XX

Our unsuitable. to is to goal suboptimal standard whom treatment is millions deliver of for care best-in-class patients the current of or the

and COVID-XX, As focused part discovery of on a progress with a continue protease make to our highly an to second-generation update provide program midyear. multipronged inhibitor, we approach we against expect differentiated also

For Phase leading stated shared the are earlier, X-week we we a for of results, as our Phase post-treatment as combination program our II II cohort XX% in HCV new we confirm study.

in [indiscernible] will details. review more results these

goal this X-week short of drug-drug risk set with is to that a care for by low enhance substantially is protease offering all program potential for for patients. tolerated Our the treatment interaction well HCV inhibitor-free current

a over execute in XXX.X December are equivalents a runway will provide XXXX. update we to strong cash Importantly, HCV on call financial today's will to million cash with Atea strategy our our turn detailed a [indiscernible] call. for with an now position as of position. financial anticipated update to and the during program. Andrea XX, of I on

Unknown Executive

Jean-Pierre. you, Thank

Slide to options, treatment crisis current health be U.S. HCV X. Despite continues Turning the to in a

effects care for improve Ruzasvir the improve the Bemnifosbuvir low potential and treatment standard treatment short substantially Recent with HCV cures treatment. free the interactions. reinfections noted of of a new more landscape. X-week of U.S. the upon current indicate less availability X.X basis. Jean-Pierre protease there statistics than the And to are inhibitor people offering earlier, yearly drug-drug HCV are in a As has million a approximately risk trends need combination to by there The these and highlight despite side on infections oral and with infected

attributes as on very our Based and prescribers, for new are slide. KOLs see with market research high these on will treatment, the next critical a you

X. Slide to Moving

prescribers X% physician regarding who co-infected as exist. that Epclusa right of While quantitative recent well this these U.S. Key emerging and antivirals in high fewer treatment. of particularly unmet market still hand treatment introduction contraindications Mavyret, has needs of conducted unmet with as needs are significant are treatment, were only HCV Atea unmet as XXX the needs HCV reported there by direct-acting slide. on the over research length or patients the detailed transformed shorter In research in of physicians higher efficacy no of HIV

approximately enroll note patients DAA-naive to Please X combination once XXX currently, regimen, Phase of open-label XXX complete daily Slide of XX% do stations Bemnifosbuvir of particular XXX prescribers. milligrams of genotypes. X to study not shorter that in durations with milligrams up Ruzasvir plan to all weeks. of and II treatment their convenient We outlines for our treatment importance making across

or SBR at week biological used was response to be II the reinitiate X of complete enrollment this primary XX study decision Phase criteria as The the week the and sustained In SCR at is will study. reported initial study completion. all endpoint to for patients cohort, the at

the demographics baseline cohort study The cohort the years the only. age old. of non-cirrhotic II [indiscernible] of Phase X Slide Bemnifosbuvir in patient of was and comprised Ruzasvir. of This XX characteristics patients and leading highlights open-label patients were median

second more However, also note II which patients please line [indiscernible] border Phase that stage liver In a cirrhosis will cirrhosis. have with is of study cirrhotic of the the part advanced XX be involved. stage, disease patients FX,

Moving XX. to Slide

Therefore, of final complete from this January, HCV. confirmed today we patients genotypes. that line treatment By in X, cohort top the We had support XX% X-week Phase XXXX. patient up treatment you of near X-week enrollment individual all study very XX the this to the for in load across the this leading In on-treatment an patients of results the only combination all kinetics to compared data. favorably II the shows share quantification. with anticipated [indiscernible] all week half the regimen post in reinitiated viral with are and or rapid below kinetics results since [indiscernible] limit study excited of across via approved to XXX genotypes in cohort second lower

Ruzasvir On discontinuation and mild. the generally safe Bemnifosbuvir adverse cohort of were were and events Slide There combination XX, events, no and adverse serious in this no of XX tolerated drug-related patients. mostly well were

cohort XX. in the and we increasing Turning XX To sites representative the II to in XX data, to January our based on countries. trial of this the advance enrollment genotype footprint reinitiated approximately distribution for -- we Phase help are clinical HCV involvement Slide in to study's remainder positive progress leading achieve summarize

addition, of over are dose conducting selection the of III tablet, the I program subsequent the for XXXX, U.S. half we will first fixed the In be and for Phase commercialization. which the studies combination Phase in used in evaluated

of We initiated the this year. program will anticipate around end Slide XX. Phase that the III be

will provide to Janet to an turn COVID-XX our Next, trial. III update our we Phase program. the I'll discuss over SUNRISE-X, call on

Janet Hammond

not ongoing the and Health is the believe suitable a serious a high according to care Organization. is millions that bemnifosbuvir clinical to compelling of of continues the to be an that low to We to for effective Good will pathogen issue. preclinical of remain millions a COVID-XX a profile whom tolerability patients. potential drug-drug an COVID-XX believe and afternoon, and current risk the with a safe COVID-XX for [indiscernible]. to differentiated ACO treatment of of for barrier is and treatment we the deliver favorable for And interactions, World COVID-XX resistance option. has Thanks, everyone. of endemic concern become patients choice for standard established

particular, patient for today. correlated enrollment into Slide with latest seeing been responsible by has patients XX. [indiscernible] wave. approximately the robust In of enrollment have extensive the footprint, U.S. we've the XX% experienced strong in where our Moving variable winter to we and are Sunrise-X enrollment sites enrolled

to the cohort, to Sunrise-X and in share despite of monotherapy past during the the majority first quarter. We're second second analysis, is analysis continue to anti-virals. of occur patients analysis. second of the March for DSMB enrollment availability The cohort X,XXX expected interim to today monotherapy triggering be oral with in The other meet in the expect excited interim interim reached we globally the the you enrolled patients the that

are the DSMB and towards Just to remind primarily safety [indiscernible]. geared reviews you,

as The risk with winter, against are predicted for underlying oral severe are far similar infection CDC showing protect patient's year. and U.S. last the to the and to severe to by curved [indiscernible] trends this important vulnerable critically immunocompromised therapeutics factors infection So most respiratory high elderly, remain the complication. diseases those hospitalization

regardless X Turning or milligrams of global is III placebo bending of To XXX trial. Phase or drug and criteria with BID moderate before XX. concurrently our our into vaccination of Sunrise [indiscernible] status. mild randomized, double-blind the go study less to on available Phase with cost COVID-XX, placebo-controlled. standard outpatients III The days administered on now study the set X high-risk care. The on the is or randomization. locally focused Slide start, detail inclusion I'll

depending primary the cohort monotherapy There care on supportive The are the received. of type comprises care population. X populations study of standard analysis

standard approximately of COVID-XX local of of including endpoint combination day hospitalization cohort monotherapy part the The is primary for XX the in includes other drugs. and the compatible which patients X,XXX the care, will study through with be as analysis, While population, support death patients. secondary treated all-cause care or antiviral

The are the reflecting were recognized medicare medical hospitalizations secondary endpoints death, designation patients. Track for symptom attended visits rehabs. bemnifosbuvir, and remains COVID-XX-related granted COVID-XX Fast that year, we for unmet need Last and

seeing with strong clinical robust we're hand to I'm enrollment X trends. discuss execution to the team our operational Overall, for marketing bemnifosbuvir. to John? John Sunrise opportunity from for call going the over now

John Vavricka

Thank you, Janet.

month, million latest to XX. infection XXX,XXX know very in scripts We a antivirals The robust winter treat rates. prescription scripts the with Last reflects U.S. total antivirals oral demand oral X.X was to Slide which the for COVID and written. with that correlates were demand XXXX approximately of surge. for Turning the approximately the

commercial On antivirals last markets such payer the to year, next began transitioning Medicaid market as oral private COVID-XX insurance. XX. Medicare, and traditional Late slide, the Slide for

with are opportunity $X to over have an years antivirals with Oral using global turn COVID-XX an there remain $X to billion COVID-XX Atea's due key market there with the [indiscernible]. U.S. annual oral for Projected come. retail expected believe IQVIA estimated Andrea multibillion-dollar billion, expand paxlovit and We I'll this still prescriptions to the over limitations. products need patients to for discuss with drug-drug to market antiviral to to only X unmet issues therapeutics opportunity and annual each demand interactions now safety is opportunity a and is to that financials. critical suggests gaps, call tolerability of

Andrea Corcoran

you, John. Thank

in full an financial fourth quarter full COVID-XX and in this Phase versus the XX. relatively of Ruzasvir and of and issued and XXXX. the quarter driver versus fourth operations containing the trial for R&D quarter investing our the fourth the of XXXX. I'll quarter of expense to Jean-Pierre for over through treatment [indiscernible] our was mentioned, period marketable XXXX. was administrative Jean-Pierre $XXX.X as securities the turn quarter cash are expenses expense period Slides statement cash in full increase clinical cash, year our year flat closing Phase As for higher versus of reiterating marketable remained to with balance, for corresponding call are on The XXXX. the was release fourth hepatitis corresponding current a XX sheet to At we in for runway of our and period combination and III and a remarks. plans, earlier and balance Interest year equivalent afternoon, fourth result we corresponding year The guidance our the increased X end XXXX. XXXX, back C. on the II higher in and and the There related our million. XXXX . General full the the with mentioned, trials press results the yield Based the in bemnifosbuvir SUNRISE external XXXX interest expense rates. higher the primary income This and of now clinical securities for

Jean-Pierre Sommadossi

Thank across X execution operational our Andrea. In year following programs. solid you, a closing, clinical

XXXX sets to Our a momentum transformational HCV and program. for up both our Carbon-XX milestone which clinical us

III clinical the milestones second half results first For anticipate second interim the global first analysis The top quarter XXXX. XXXX. our expected COV-XX, XXXX meaningful trial, quarter the interim of second log in Phase as we in beginning of a analysis from by in of followed the was

II results the reporting during study anticipate we XXXX. of enrollment and Phase completing second half of our HCV, For

around to and cohort. safety and we We a leading have end the of by in the are target continued III initiation the Phase of year, the encouraged extremely SVRX results

gap have which markets, of multibillion-dollar products. to that of current currently only and targeting are approved, if our needs fill the very unmet primary comprised differentiated are believe the opportunity, are and in candidates the We product products. X blockbuster medical each become We

I'm ahead and in work with global excited less as Aptar our to shareholder XX We with particular, ability create very opportunities proud the and market develop is efficiency year. of very about meaningful which the conducting financial company degree significant innovative is throughout opportunities a hard with are as and in commercialize the are team multibillion-dollar discipline. well employees, studies disease than In confident products a high value. X with of

back I operator. With the over will the turn that, call to

Operator

Eric first our And Instructions] [Operator from JPMorgan. of question will come Joseph

Eric Joseph

A us. couple from

the compared across on made, just combo? alternative commercially patients option. for other Sunrise-X. safety monotherapy is you on you the of completion monotherapy picking terms about Do different that Or significance inhibitor Just guess, you'd a HCV being population. an enrollment protease-based just non [indiscernible]. to of accrual JP to primary side, highlight? guess it a study And do there being visibility a about that? comment how up the versus the What's have in terms mechanism of sort in more percent Is I potentially on advantage have available sizable what of the those of I you visibility are arms, analysis the apportioned in

Jean-Pierre Sommadossi

an Thank questions. let's question. But you, Eric. you importance There is and some COVID-XX little Great start to granularity to . want bit Janet, definitely with Eric. a give differentiation. the

Janet Hammond

Thank you, the Eric, for question.

combination discretion in patient, of mean, prescribers think the the the in say the extensively might that patient. then when first is arm. and in that But don't monotherapy at patients. the question very think, we vast to as strong combination And being of the and associated we are to meetings that probably car. as seen very deters prescribing . And on potential proceeding is appropriate So I No, combination cases visibility a curved months followed -- quite who that frequently, the and if hot we're [indiscernible] all, is the downward apportioned obviously, And are I people in accrual of I in think the the until the believe is patients encouraged think they this but with to sees can are people we how at complete is some interactions regard really get by And summer your this We've the regard. least course, we've -- -- versus dependent regards around I surprising which for of reasons towards monotherapy for to the cases we past, actually educated winter are in again. at potential to number doors but arm, any calculations to just a I say quite well. assigned drug patients have the I therapy our that moving we the of investigator when season, the in to in therapy prescribe that's to monotherapy. from they majority combination actually investigation treatment, for what if that extensive observed ritonavir enrollment trend

So on we're to we'll have that, somewhat dependent and see.

Jean-Pierre Sommadossi

party to think the inhibitor. survey to when about are I from pure the substantial with especially talking HCV, importance interaction treatment a we of infected with really combination if third you're a where the lack have have questions, the have in related patients inhibitor a we of of if XX% you [indiscernible] exemplify going drug-drug HCV HIV So

-- John, an also it want John, I a important standpoint from is want really on from that a but will standpoint. address patient and expand are do a a not you from talking, that to we important standpoint? commercial answer this just ask So then really [indiscernible] differentiation, maybe to commercial and you is that here

John Vavricka

Sure.

shorter And drug what highlight look shares, load the as in having other food a better. to X treat us because, Eric, with a Rx market obviously almost in new -- able X the our difference the And weeks a are really favor earlier this treat to XX-point bit to clinicians at time the no [indiscernible] DDI is of a being obviously, also about and little duration, standpoint, more a particularly in the is important that than protease commercial presentation, XX, despite shorter being be [indiscernible] finding also to such [indiscernible] treatment So inhibitor. And potential. has effect interaction there's even you low when is share as for there's a also -- from advantages versus to important [indiscernible]. mentioned

also tell And maybe as so should some that us well. things

Jean-Pierre Sommadossi

answer [indiscernible] discussion standpoint from ahead? patient with prescriber, will until a go your I

Janet Hammond

Yes.

that. medical I trying that combines it's a what perspective, really of the a best drug-drug these a common here sense therapy, drugs from are the that And as we're So [indiscernible] we're quite and develop best-in-class actually almost without the think [indiscernible] are regimen X pump an which protease Mavyret contraceptive things talking interactions regimen [indiscernible] something everybody class. and and to of is like that like antiretroviral inhibitors, best the on about week have proton in statins, that inhibitors common

protocol indicated. important on So to they redo as the talk were we when research when this trying regimens. the of is very KOLs also very attributes participate the actually this of develop But -- and of field and the has for to that patients market the could both our both best were in bringing our regimen, actually them clinical we trial all excited best-in-class

Operator

next will Skor question And Stanley. from be of Morgan coming our Maxwell

Maxwell Skor

strategy global your how over bit for was a on program the you're your about elaborate quarters? potential while Given allocation you HCV spend advancing your how can capital several preparing should basically, we position, COVID launch and a strong hoping in financial next think I

Jean-Pierre Sommadossi

indicate investment to actually UA. risk to I'd the you maybe we will in the substantial an to launch, have for fortunate in want prior If address approval to approval. get we if just at to Andrea, supply. But manufacturing that we [indiscernible] like the question, are

we information additional provide closer will we get to So launch. as

that, [indiscernible] with Andrea? So

Andrea Corcoran

Yes. Thank you, question. and thanks, the Jean-Pierre, Max, for

XXXX. the type our review as as quarter-over-quarter Expenses really continue And for think statements, very program. expect you've in the investments would for XXXX. both of to we we I are you when in program see FC or a COVID-XX we'll So as but seen increasing the measured way well to discipline limited the same increase have chance exercise in the financial

The commercialization, before begins you've preparing wind Phase to III we said. for Phase for begin will program But III nonetheless, will as for be COVID hep down the C.

point. So there we additional and that at will will funding that be be activities

expenses but increase, 'XX the 'XX to expected for So in and very way. are a measured

Operator

will be from question next coming ISI. Miller our Evercore Jon of And

Jessica Hanitta Hui

for questions, X on John -- have X I hep Jessica I if is on on the This front. may. COVID, C Miller. X

top So the for the line COVID, in second half so X you expected year. of SUNRISE said data

think how think size making appreciate -- that about various infection the preexisting scenarios should market a How smaller the does occur? the how possibly well placebo So vaccination maybe can immunity like and/or from effect and that affect rates, can we the data that scenario, trial [indiscernible] to then question. met have about endpoint scenario And direction a then primary bear not case follow-up in comp limited. should worst-case the direct may the is be and company also how we I

Jean-Pierre Sommadossi

Janet, address do to please? the you like question,

Janet Hammond

Thank Jessica. you,

yes, it realizes and in with that hospitalizations an going we're exposure than [indiscernible] fortunately, So and particular, to are delta severe frequency prior less think the I we all-time through, wave think, the to when vaccination high. everybody was I severity COVID-XX,

in so the there the the a study about -- designed where reported to XXs think the was efficacy active comparable is delta outpatient placebo groups. between and I difference recently most Our study, is in what in show the

what And expecting we're to that's so see.

about the particularly And difference. hospitalizations, and when you're talking death that meaningful hospitalization patients is worst an of and still outcomes. I course, important are think high-risk and

those disease, important. prevent severity that's X the be so really and reduce And can going think if I to of

Jean-Pierre Sommadossi

Janet. ahead, Go

go Sorry, ahead.

Janet Hammond

ask question Yes, point. you on wanted primary the I around where to other scenario was you if Jessica's to fail we end just achieve to with the follow going

Jean-Pierre Sommadossi

. Yes, go ahead.

Janet Hammond

Okay.

fast should will in to successful. mean, I to avenues we're of there wherever we decision mentioned, have under pursue see help do are make And what terms is X in the that But trends? have, that, of proceed. I it's think if to for So to analyses FDA also a I those to things to unable I the allow we is consideration one DSMB that of looking us -- proceed certainly, are we patients think has mean, designation track further would not assess interim been us projecting be we number how to with as

So aware presenting thinking well, and at certainly are update we're the are move the as things about. look of and we those think scenarios to unless results you But forward forward need I and moment, that forward. moving to we

Jean-Pierre Sommadossi

you, the [indiscernible] I Thank [indiscernible]. to it's an to is it high first was -- And NIH actually, [indiscernible]. and actually that I XX% recently reported very I oral what add of the actually telling Janet risk impact wanted -- question think so that should only XX% of get therapeutic think

So of many love of very the it. reasons likely [indiscernible] of limitation the

opportunity and will you and the safety as for in Janet there believe huge has Jessica, number of can face the including efficacy built product, the we even study here a results a challenges of you this see of been low maximize that So best-in-class for event, with but that drug. is way the recognize we terms this that

on another as have well? So . I may understand you question HCV

Jessica Hanitta Hui

Yes.

in the achieve ensure and protocol [indiscernible] Phase here thus So on so especially already ones that X be adherence, are unmet Phase seen already they context you we cured to patients presumably guys clinical already. here. III going that the existing therapies the the SVRX. patient can bad hep drug optimize How II C is to that for unable with good else that with need after and compliance since compliance at existing you're there's regimens, sites or an are And plan [indiscernible] the lacking know the do program, we've given

Jean-Pierre Sommadossi

some That's a great question, [indiscernible], spent we that. on time quite Jessica.

So [indiscernible], you address question? like would to the

Unknown Executive

great Yes, it a is question.

not C. are trials a part, of that issues in just of population now the bit treatment population patients right doing in we have but from that are benefit who now. need also right patients durations. of there of is large a really in is a and those taking high the or ex they hepatitis nature IV compliance mix drug think general unmet drug just that short are part the I users and The -- very it's IV users, are of drugs patients,

offering short So the the duration, drugs a towards I the patients sometimes excited they because end I you're general we'll in the to think by issues addressing then at take that. of of have compliance very already but some forget all beginning, experienced think are treatment, treatment

the duration helped. already X-week So

We, is comparator. them And what's have III checking of patients, that with them, the in. course, to in very of we're a going Phase measurements calling the important have regular bringing

So issues patients that the general. the affect to these population, compliance And going how kind includes which will arms behaving noncompliant is both with there, today's you're randomized. patients in equally comparator because the really are of see in are

Jean-Pierre Sommadossi

And obviously, we any regulatory will finalize protocol the with authorities.

So -- program. Phase is a clear initial . that our on but comparator our interaction, based it's required for III

Operator

from Roanna next our will with Partners. be And Leerink coming Ruiz question

Rosa Chen

This on Leerink is Rosa Chen for Roanna at Ruiz Partners.

Just a couple from us.

First on COVID.

think patients III, the the And most which could offer can therapy available phase you're arm? any leverage on thoughts data subpopulation that [indiscernible] So thinking the from differentiated combination enrolling you do you high-risk currently all the various profile in antivirals? of from how

Jean-Pierre Sommadossi

please? you like do question, Janet, to address the

Janet Hammond

Sure.

I the with and organ for a the patient particularly, last I risk patients, XX elderly, think transplant really immunocompromised. regard, And patients. there's mean, been those think think few high have showing particularly that most couple [indiscernible] there population, that in regard but and in the I I interesting, quite that I highly think it's above are solid publications So the months, of to high-risk

times do they risk of COVID. getting with they when seem their ill many it reduce infected get doesn't severely become However to really vaccinated,

ones patient the are which is the are be likely to the there these think great probably I populations, So where benefit.

multiple populations inhibitors drug be with patients protease And Jean-Pierre patient much we've think mentioned, than Baliotti an these and are to, I ideal alluded particularly nucleoside think that these I another reason potential the as for with think interactions, such I why mean antagonists. that drug higher And medications. would concomitant is I for as are ultimately, as on is

with monoclonal so are then in group to we're a most think And hope antibodies where and to to to pace to with is combination mentioned the going his the which been a developed the know, show protease Jean-Pierre receive fortunate as been frequently, being have, able been [indiscernible]. to and really as later for regard ourselves. the the ineligible But in receive past in I these It's of year. educate -- do more that as you the to the enough evolution haven't to anibodies. monoclonal COVID such drug have And what past keep have the which remarks, populations patient think they're inhibitor, we I in information actually because we important, able

see able think how potentially reduce improve with so to protease inhibitor to able is better. being and in and combination particular, to synergy [indiscernible] symptoms therapy And a I patients combination [indiscernible] allow provide in and

And and drug interactions, genetics and also at such load as [indiscernible] [indiscernible]. looking safety we're [indiscernible] things

I of best move in further information how these and as them line. important down think drugs use understanding to that maximize all is we the

Rosa Chen

think PK And we actually cirrhosis then -- considered co-infection efficacy semesafavir has and [indiscernible] Phase that your you HIV decompensated of without the population leading should and in patients to are with in III. then also about and including those your on And HCV, cirrhosis. patient the cohort? how cirrhosis compensated compared in

as fruit label you target a And could to low-hanging a then are these Epclusa. who it's similar similar patients approved? it's separately, So if was that pursue

Jean-Pierre Sommadossi

question, and So you want as address to to well. the we have maybe comment maybe [indiscernible], start a then

So [indiscernible] .

Unknown Executive

we even condensated really were in the viral saw you are which we have PK/PD cirrhotic. Well, FXs, the think Yes. the that as in don't anticipate data borderline the PK, shown and PK even very kinetics changes major I fast in or kinetics

cirrhotics. is we've seen in be So we PK for compensated trials think and that also the should the that same. That previous -- the

the is cirrhotic population. great For decompensated a

little are a bit later. we target it. that probably think It's to I going

we need are a like certainly, Phase considering unmet great you inclusion HIV, trial. population. the It's III For in said,

Jean-Pierre Sommadossi

for that Yes. patients. believe, because decompensated the comment have No. advance you of which X be, the which approved to eliminate a foresee and [indiscernible], right Actually, see just is we now, only ribavirin those We combination Epclusa treatment, potential a obviously, patients, major X would [indiscernible]. we in

that not Now that are trial, very population difficult, deaths. patient in a you let's very forget this some to going likely is have is

the week success XX require of that, best length less [indiscernible] X very But this shared do these a Phase have would that the we that just commitment. unless maybe treatment chance with an III that a there, post you of highly program definitely, be importance with differentiated and go obviously, So already be ribavirin. definitely likely population authorities more of part we . the will as And the to obviously, patient population probably we the regulatory with not before. week, patients of the will but with what foresee want NDA not request of elimination than

Operator

the Jean-Pierre turn closing to to I would now for remarks. conference back like

Jean-Pierre Sommadossi

earnings all you And fourth continued full conference as Thank for joining support. you quarter and XXXX call. your our thank for year well

Operator

this and concludes today's Ladies gentlemen, conference.

now disconnect. may You

Atea Pharmaceuticals (AVIR) 28 Feb 242023 Q4 Earnings call transcript